Getinge (OTCMKTS:GNGBY) Hits New 1-Year High – Time to Buy?

Getinge (OTCMKTS:GNGBY) hit a new 52-week high during trading on Monday. The stock traded as high as $28.03 and last traded at $28.03, with a volume of 408 shares trading hands. The stock had previously closed at $26.82.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. UBS Group assumed coverage on shares of Getinge in a research report on Wednesday, September 2nd. They issued a “hold” rating on the stock. Nordea Equity Research cut shares of Getinge from a “buy” rating to a “hold” rating in a research report on Monday, August 31st. Pareto Securities downgraded shares of Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 24th. Finally, Zacks Research downgraded shares of Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 17th. Four investment analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Getinge Price Performance

The company has a 50 day simple moving average of $25.46 and a 200 day simple moving average of $22.65. The company has a market capitalization of $7.62 billion, a price-to-earnings ratio of 20.41 and a beta of 0.89. The company has a quick ratio of 0.74, a current ratio of 1.31 and a debt-to-equity ratio of 0.26.

Getinge (OTCMKTS:GNGBY) last released its quarterly earnings data on Wednesday, October 21st. The company reported $0.32 earnings per share (EPS) for the quarter. Getinge had a net margin of 8.20% and a return on equity of 11.55%. The company had revenue of $875.58 million during the quarter. As a group, research analysts predict that Getinge will post 1.36 EPS for the current year.

Getinge Company Profile

Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support patient care, surgical procedures, infection prevention and the development and production of pharmaceuticals and other medical products.

The company’s portfolio includes equipment for intensive care and cardiovascular procedures, operating-room systems, surgical instruments, sterilization and disinfection solutions, and products used in laboratories and biopharmaceutical manufacturing.